Search results for "pharmacophore"

showing 10 items of 71 documents

Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?

2000

The identification and characterisation of the isoenzyme cyclooxygenase 2 (COX-2) stimulated investigations to develop efficient non-steroidal anti-inflammatory drugs with reduced side effects compared to standard NSAIDs. This review will focus on the structural features needed to achieve COX-2 selectivity. Five structural classes can be identified together with a class bearing little or no resemblance to one another in their molecular structure. The most interesting point is the very distinct structure/activity relationship. On the one hand only minor modifications to a particular compound induce a drastic change in its COX selectivity and on the other hand the structural prerequisites in …

Polarity (physics)StereochemistryComputational biologyBiochemistryPyrrole derivativesStructure-Activity RelationshipProstaglandin-Endoperoxide SynthaseDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsPharmacologyCyclooxygenase 2 InhibitorsMolecular StructureChemistryAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryMembrane ProteinsRecombinant ProteinsIsoenzymesMechanism of actionCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesBenzene derivativesLipophilicityMolecular Medicinemedicine.symptomPharmacophoreSelectivityCurrent Medicinal Chemistry
researchProduct

Targeting SARS-CoV-2 RBD Interface: a Supervised Computational Data-Driven Approach to Identify Potential Modulators

2020

Coronavirus disease 2019 (COVID-19) has spread out as a pandemic threat affecting over 2 million people. The infectious process initiates via binding of SARS-CoV-2 Spike (S) glycoprotein to host angiotensin-converting enzyme 2 (ACE2). The interaction is mediated by the receptor-binding domain (RBD) of S glycoprotein, promoting host receptor recognition and binding to ACE2 peptidase domain (PD), thus representing a promising target for therapeutic intervention. Herein, we present a computational study aimed at identifying small molecules potentially able to target RBD. Although targeting PPI remains a challenge in drug discovery, our investigation highlights that interaction between SARS-CoV…

Protein domainPneumonia ViralDruggabilityDrug Evaluation Preclinicalprotein-protein interactionsComputational biologyBiologyMolecular Dynamics SimulationPeptidyl-Dipeptidase AMolecular dynamics01 natural sciencesBiochemistryMolecular Docking SimulationAntiviral Agentsdockingmolecular dynamicProtein–protein interactionSmall Molecule LibrariesBetacoronavirusProtein DomainsDrug DiscoveryHumansGeneral Pharmacology Toxicology and PharmaceuticsPandemicsPharmacologyFull Paperpharmacophore010405 organic chemistryDrug discoverySARS-CoV-2Organic ChemistryCOVID-19Small molecule0104 chemical sciencesProtein-Protein InteractionMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)Spike Glycoprotein CoronavirusdockingMolecular MedicineAngiotensin-Converting Enzyme 2PharmacophoreCoronavirus InfectionsProtein Binding
researchProduct

Molecular modelling and QSAR in the discovery of HIV-1 integrase inhibitors

2007

The treatment regimens for the HIV-1 have mainly included reverse transcriptase or protease inhibitors but their long-term clinical utility is limited by severe side effects and viral drug resistance. A new attractive target for chemotherapeutic intervention can be the Integrase enzyme, that mediates the integration of HIV-1 DNA into a host chromosome, for which there is no known counterparts in the host cell. A number of derivatives have been found to inhibit IN in in vitro assays, but no successful drug based on them has emerged so far, although many compounds have been proposed. Moreover most of the inhibitors do not belong to a very precise structural class: this fact makes these compou…

Quantitative structure–activity relationshipProteasebiologymedicine.medical_treatmentIntegrase inhibitorDrug designGeneral MedicineComputational biologyDe novo design Docking HIV-1 integrase inhibitors Molecular dynamics Molecular modelling Pharmacophore QSARBioinformaticsIntegraseDocking (molecular)Host chromosomeDrug Discoverybiology.proteinmedicineMolecular MedicinePharmacophore
researchProduct

Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors

2019

[EN] The development and advancement of prostate cancer (PCa) into stage 4, where it metastasize, is a major problem mostly in elder males. The growth of PCa cells is stirred up by androgens and androgen receptor (AR). Therefore, therapeutic strategies such as blocking androgens synthesis and inhibiting AR binding have been explored in recent years. However, recently approved drugs (or in clinical phase) failed in improving the expected survival rates for this metastatic-castration resistant prostate cancer (mCRPC) patients. The selective CYP17A1 inhibition of 17,20-lyase route has emerged as a novel strategy. Such inhibition blocks the production of androgens everywhere they are found in t…

Quantitative structure–activity relationshipStereochemistry01 natural sciencesBiochemistryStructure-Activity Relationship3D-QSAR pharmacophore modelDrug DiscoveryCytochrome P-450 Enzyme InhibitorsHumansStructure–activity relationshipCYP17A1 InhibitorMolecular BiologyDensity Functional TheoryVirtual screeningDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryProspective computational designSteroid 17-alpha-Hydroxylasecomputer.file_format1720-lyase selective inhibitionProtein Data BankLyase0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)CYP17A1 inhibitorsMetastatic-castration resistant prostate cancerPharmacophorecomputer
researchProduct

Antiproliferative agents that interfere with the cell cycle at the G(1)-->S transition: further development and characterization of a small library o…

2008

In this continuation of our research on derivatives containing the stilbene privileged structure or that are derived from it, we report the results of further studies carried out on the previously initiated collection of compounds. We used a parallel synthetic approach to rapidly obtain small sets of compounds and started the annotation of the library in progress by calculating some physicochemical properties to be eventually correlated with biological activities. A pharmacophore for the antiproliferative activity was also built to summarize the features of the library. We evaluated the antiproliferative and pro-apoptotic activities of all compounds as well as the cell-cycle effects of some…

StereochemistryCellular differentiationAntineoplastic AgentsApoptosisHL-60 CellsBiochemistryS PhaseSmall Molecule Librarieschemistry.chemical_compoundInhibitory Concentration 50Biological profileCell Line TumorDrug DiscoveryStilbenespharmacophoresHumansGeneral Pharmacology Toxicology and PharmaceuticsPhosphorylationPharmacologyChemistryOrganic ChemistryG1 PhaseRetinoblastomaSmall Molecule LibrariesG1/S transitionCell DifferentiationCell cycleFlow CytometryCombinatorial chemistryantitumor agentAntiproliferative AgentsMolecular MedicineTriolcell cyclePharmacophoreC-C couplingK562 Cells
researchProduct

Icosahedral carboranes as scaffolds for congested regioselective polyaryl compounds: the distinct distance tuning of C–C and its antipodal B–B

2019

Four-fold aryl substituted o-carborane derivatives with defined patterns of substitution at the antipodal region of the cluster carbon atoms have been achieved. It is proven that this region is congested but lacks steric hindrance. Also, the two antipodal sites Cc–Cc and B9–B12 are affected very distinctly by electron donor substituents.

Steric effectsIcosahedral symmetryAntipodal pointElectron donorCrystal structure010402 general chemistry01 natural sciencesCatalysischemistry.chemical_compoundMaterials ChemistryCluster (physics)BoronO-carboranes010405 organic chemistryChemistryArylMetals and AlloysRegioselectivityGeneral Chemistry3. Good health0104 chemical sciencesSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsPharmacophoresCrystallographyCrystal-structureCeramics and CompositesChemical Communications
researchProduct

Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds

2021

AbstractThe five-membered pyrrolidine ring is one of the nitrogen heterocycles used widely by medicinal chemists to obtain compounds for the treatment of human diseases. The great interest in this saturated scaffold is enhanced by (1) the possibility to efficiently explore the pharmacophore space due to sp3-hybridization, (2) the contribution to the stereochemistry of the molecule, (3) and the increased three-dimensional (3D) coverage due to the non-planarity of the ring—a phenomenon called “pseudorotation”. In this review, we report bioactive molecules with target selectivity characterized by the pyrrolidine ring and its derivatives, including pyrrolizines, pyrrolidine-2-one, pyrrolidine-2…

Steric effectsPyrrolidinesMolecular StructureChemistryDrug discoveryEnantioselective synthesisStereoisomerismGeneral ChemistryReviewAnti-inflammatory and analgesic agentsRing (chemistry)Combinatorial chemistrySettore CHIM/08 - Chimica FarmaceuticaPyrrolidineProlinolPyrrolidinechemistry.chemical_compoundAntidiabeticsDrug DiscoveryPseudorotationHumansAnticancer and antibacterial agentsPharmacophoreCentral nervous system diseases
researchProduct

Role of hydrophobicity on the monoamine receptor binding affinities of central nervous system drugs: a quantitative retention-activity relationships …

2004

Abstract Biological action and activity reflect an aspect of the fundamental physicochemical properties of the bioactive compounds. As an alternative to classical QSAR studies, in this work different quantitative retention–activity relationships (QRAR) models are proposed, which are able to describe the role of hydrophobicity on the binding affinity to different brain monoamine receptors (H 1 -histamine, α 1 -noradrenergic and 5-HT 2 -serotonergic) of different families of psychotherapeutic drugs. The retention of compounds is measured in a biopartitioning micellar chromatography (BMC) system using Brij-35 mobile phases. The adequacy of the QRAR models developed is due to the fact that both…

Steric effectsQuantitative structure–activity relationshipStereochemistryClinical BiochemistryQuantitative Structure-Activity RelationshipSerotonergicBiochemistryAnalytical ChemistryReceptors Biogenic AmineReceptors Adrenergic alpha-1AnimalsReceptors Histamine H1ReceptorMicellesChromatographyChromatographyMolecular StructureChemistryCell MembraneBrainCell BiologyGeneral MedicineAffinitiesMonoamine neurotransmitterSerotonin 5-HT2 Receptor AntagonistsPharmacophoreReceptors Serotonin 5-HT2Quantitative analysis (chemistry)Central Nervous System AgentsJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

In Silico Design, Synthesis and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity

2022

Telomerase, a reverse transcriptase enzyme involved in DNA synthesis, has a tangible role in tumor progression. Several studies have evidenced telomerase as a promising target for developing cancer therapeutics. The main reason is due to the overexpression of telomerase in cancer cells (85–90%) compared with normal cells where it is almost unexpressed. In this paper, we used a structure-based approach to design potential inhibitors of the telomerase active site. The MYSHAPE (Molecular dYnamics SHared PharmacophorE) approach and docking were used to screen an in-house library of 126 arylsulfonamide derivatives. Promising compounds were synthesized using classical and green methods. Com…

SulfonamidesRPharmaceutical ScienceAnticancer compounds; Arylsulfonamide; Docking; Molecular dynamics; Pharmacophore modeling; Structure-based drug design; Sulfonamides; Telomerase inhibitorsMolecular dynamicsSettore CHIM/08 - Chimica FarmaceuticaArticleDockingRS1-441Anticancer compoundsTelomerase inhibitorsPharmacy and materia medicaDrug DiscoveryArylsulfonamideMedicineMolecular Medicinesulfonamides; arylsulfonamide; anticancer compounds; telomerase inhibitors; structure-based drug design; pharmacophore modeling; docking; molecular dynamicsStructure-based drug designPharmacophore modeling
researchProduct

TOWARD ENRICHED VHTS FOR CDK2 INHIBITORS: MOLECULAR DYNAMICS, PHARMACOPHORE MODELLING, AND DOCKING

2019

Cyclin-Dependent Kinases-2 (CDK2) are members of the serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicates that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, we collected one-hundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket submitting to short MD simulations (10ns) and free energy calculation by means of MM-GBSA. The calculate ∆G values have been compared with …

VHTS CDK2 INHIBITORS MOLECULAR DYNAMICS PHARMACOPHORE MODELLING DOCKING
researchProduct